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Measurement of social cognition in treatment trials 
remains problematic due to poor and limited psychomet-
ric data for many tasks. As part of the Social Cognition 
Psychometric Evaluation (SCOPE) study, the psychomet-
ric properties of 8 tasks were assessed. One hundred and 
seventy-nine stable outpatients with schizophrenia and 
104 healthy controls completed the battery at baseline 
and a 2–4-week retest period at 2 sites. Tasks included the 
Ambiguous Intentions Hostility Questionnaire (AIHQ), 
Bell Lysaker Emotion Recognition Task (BLERT), Penn 
Emotion Recognition Task (ER-40), Relationships Across 
Domains (RAD), Reading the Mind in the Eyes Task 
(Eyes), The Awareness of Social Inferences Test (TASIT), 
Hinting Task, and Trustworthiness Task. Tasks were eval-
uated on: (i) test-retest reliability, (ii) utility as a repeated 
measure, (iii) relationship to functional outcome, (iv) prac-
ticality and tolerability, (v) sensitivity to group differences, 
and (vi) internal consistency. The BLERT and Hinting task 
showed the strongest psychometric properties across all 
evaluation criteria and are recommended for use in clinical 
trials. The ER-40, Eyes Task, and TASIT showed some-
what weaker psychometric properties and require further 
study. The AIHQ, RAD, and Trustworthiness Task showed 
poorer psychometric properties that suggest caution for 
their use in clinical trials.
Key words: schizophrenia/measurement/reliability/ 
validity/emotion processing/social perception/mental 
state attribution
Introduction
The importance of social cognition for schizophrenia 
research is substantial and growing rapidly, largely based 
on data showing that social cognition predicts func-
tioning1,2 and that treating social cognitive impairment 
leads to improvements in real-world social outcomes.3–5 
However, the paucity of well-validated measures of social 
cognition remains an ongoing challenge for productive 
research. Most existing measures have poor psychomet-
ric properties, or their psychometrics are not known. 
Inadequate measurement can compromise validity and 
reproducibility of findings and limits treatment develop-
ment and evaluation by rendering it difficult to accurately 
assess treatment response. 
The Social Cognition Psychometric Evaluation 
(SCOPE) Study seeks to address this problem by sys-
tematically evaluating the psychometric properties of the 
most widely used measures of social cognition. Phases 
1 and 2 of the project utilized expert surveys and the 
RAND Appropriateness Method of consensus develop-
ment to select the best existing measures based on cur-
rent knowledge of their psychometric properties and 
their potential for use in clinical trials. Eight measures 
of social cognition covering 4 domains and 1  “novel” 
category were identified.6 In phase 3, large samples of 
individuals with schizophrenia and healthy controls com-
pleted the measures to assess the reliability and validity 
of each task.
In this article, we report the results of  Phase 3 con-
stituting the initial psychometric study of  the mea-
sures’ properties. Consistent with other National 
Institute of  Mental Health measurement initiatives 
(eg, Measurement and Treatment Research to Improve 
Cognition in Schizophrenia7 and Social Cognition and 
Functioning in Schizophrenia8–10), we report data on 
those characteristics rated most important for evaluation 
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of measures to be used in clinical trials, including: (i) 
test-retest reliability, (ii) utility as a repeated measure, 
(iii) relationship to functional outcome, and (iv) prac-
ticality and tolerability.11 Sensitivity to change was 
also identified as a key criterion for clinical trials; how-
ever, the lack of  a treatment component in this study 
precluded evaluation of  this criterion. As the evalu-
ated measures are used extensively in nonintervention 
research, we also report data on the sensitivity of  these 
measures to differences between patients and healthy 
controls and internal consistency. Finally, Phase 3 con-
cluded by reconvening a subset of  the initial RAND 
Panelists and the study consultants to review the data 
and determine which tasks were appropriate for contin-
ued investigation. Recommendations of  this Panel are 
presented at the end of  the results.
Methods
Participants
The study took place at 2 sites, Southern Methodist 
University (SMU) and the University of Miami Miller 
School of Medicine (UM). Patients at the SMU site 
were recruited from Metrocare Services, a nonprofit 
mental health services provider organization in Dallas 
County, TX, and other area clinics. UM patient recruit-
ment occurred at the Miami VA Medical Center and 
the Jackson Memorial Hospital-University of Miami 
Medical Center. At both sites, healthy controls were 
recruited via community advertisements.
To be eligible, patients required a Diagnostic and 
Statistical Manual of  Mental Disorders, Fourth Edition 
(DSM-IV) diagnosis of  schizophrenia or schizoaffec-
tive disorder as confirmed by clinical interview with 
the Mini International Neuropsychiatric Interview12 
and Structured Clinical Interview for DSM Disorders 
Psychosis Module.13 Patients could not have any hos-
pitalizations within the last 2  months and had to be 
on a stable medication regimen for a minimum of  6 
weeks with no dose changes for a minimum of  2 weeks. 
Healthy controls were screened for history of  psycho-
pathology to ensure they did not meet criteria for any 
major DSM-IV Axis I or II disorders. Exclusion crite-
ria for both groups included: (i) presence or history of 
pervasive developmental disorder or mental retardation 
(defined as IQ < 70) by DSM-IV criteria, (ii) presence 
or history of  medical or neurological disorders that 
may affect brain function (eg, seizures, central nervous 
system tumors, or loss of  consciousness for 15 min or 
more), (iii) presence of  sensory limitation including 
visual (eg, blindness, glaucoma, vision uncorrectable 
to 20/40) or hearing impairments that interfere with 
assessment, (iv) no proficiency in English, (v) presence 
of  substance abuse in the past month, and (vi) presence 
of  substance dependence not in remission for the past 
6 months.
Measures
Social Cognition Measures
Attribtuional Style/Bias
The Ambiguous Intentions and Hostility Questionnaire 
(AIHQ).14 The AIHQ evaluates hostile social cognitive 
biases. Participants read 5 hypothetical, negative situations 
with ambiguous causes (ie, they could be intentional or 
accidental), imagined the scenario happening to them, and 
recorded a reason why the scenario occurred. Participants 
then used Likert scales to rate whether the other person/s 
performed the action on purpose (1  “definitely no” to 
6  “definitely yes”), how angry it made them feel (1  “not 
angry at all” to 5 “very angry”), and how much they blamed 
the other person/s (1 “not at all” to 5 “very much”). Finally, 
the participant wrote down how they would respond to the 
situation. Responses to open-ended questions were coded 
by 2 independent raters to compute a hostility bias (HB) 
index and an aggression bias (AB) index, respectively, rang-
ing from 1 to 5 (Intraclass correlation coefficients, ICC (3,2), 
ranged from .834 to .967 for the individual items). A Blame 
Score (BS) was computed by averaging Likert ratings to each 
question and then summing the 3 averages (range = 3–16).
Emotion Processing
Bell Lysaker Emotion Recognition Task (BLERT).15 The 
BLERT measures the ability to correctly identify 7 emo-
tional states: happiness, sadness, fear, disgust, surprise, 
anger, or no emotion. Participants viewed 21 10-second 
video clips of a male actor, providing dynamic facial, 
vocal-tonal, and upper-body movement cues. After view-
ing each video, participants identified the expressed emo-
tion. Performance was indexed as the total number of 
correctly identified emotions (ranging from 0 to 21).
Penn Emotion Recognition Text (ER-40).16 The ER-40 
includes 40 color photographs of static faces expressing 4 
basic emotions (ie, happiness, sadness, anger, or fear) and 
neutral expressions. Stimuli are balanced for poser’s gen-
der, age, and ethnicity, and for each emotion category, 4 
high-intensity and 4 low-intensity expressions are included. 
Participants viewed 1 image at a time and chose the correct 
emotion label for each face. Accuracy scores, ranging from 
0 to 40, were the primary dependent variable.
Social Perception
Relationships Across Domains (RAD).17 The RAD mea-
sures competence in the perception of 4 relational models: 
communal sharing, authority ranking, equality matching, 
and market pricing. The abbreviated version is comprised 
of 15 vignettes involving different male-female dyads 
that represent one of the relational models. Participants 
read each vignette and answered 3 yes/no questions about 
whether a future behavior was likely to happen given the 
described relationship. Performance was indexed as the 
total number of correct responses (ranging from 0 to 45).
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Theory of Mind/Mental State Attribution
Reading the Mind in the Eyes Test (Eyes).18 The Eyes 
task measures the capacity to discriminate the mental 
state of others from expressions in the eye region of the 
face. Participants viewed 36 photos of the eye region of 
different faces and chose the most accurate descriptor 
word for the thought/feeling that was portrayed. Four 
possible options were presented with each photo, and a 
glossary of mental state terms was provided for reference. 
The dependent measure was the total number of correct 
responses, ranging from 0 to 36.
The Awareness of Social Inferences Test, Part III 
(TASIT).19 The TASIT assesses detection of lies and 
sarcasm. Participants watched short videos of everyday 
social interactions and answered 4 standard questions per 
video that probed understanding of the intentions, beliefs, 
and meanings of the speakers and their exchanges. Total 
number correct indexed performance, and scores ranged 
from 0 to 64.
Hinting Task.20 The Hinting Task examines the ability of 
individuals to infer the true intent of indirect speech. Ten 
short passages present an interaction between 2 characters, 
and each passage ends with one of the characters dropping 
a hint. Passages were read aloud by the experimenter, and 
participants were asked what the character truly meant. If  
the first response provided was inaccurate, a second hint 
was delivered, allowing participants to earn partial credit 
for that passage. Total scores ranged from 0 to 20.
Novel Category
Trustworthiness Task (Trust)21 
This task assesses participants’ ability to make complex 
social judgments of trustworthiness. Participants rated 
42 faces for trustworthiness on a scale from −3 to 3. Faces 
were presented in grayscale and represented ethnically 
diverse males and females. The average rating across all 
faces served as the primary outcome variable.
Additional Outcome Variables
In addition to the primary outcome variables, tolerability 
and practicality were assessed for each of the social cog-
nitive measures. Task tolerability referred to the degree to 
which participants found the task enjoyable and was rated 
on a scale from 1 (very unpleasant) to 7 (very pleasant). 
Ratings of 4 indicated neither pleasant nor unpleasant. 
Practicality was operationalized as administration time.
Neurocognitive Measures
Given our emphasis on social cognition and previous work 
investigating the domains accounting for the most vari-
ance in composite scores of neurocognitive performance,22 
participants completed only a subset of the MARTICS 
Consensus Cognitive Battery.7 Assessed domains included 
speed of processing (Trail Making Test, Part A; BACS: 
Symbol Coding; and Category Fluency: Animal Naming), 
working memory (Letter-Number Span), and verbal 
learning (HVLT-R). The Wide Range Achievement Test-3 
Reading subscale provided an estimate of premorbid IQ.23
Functional Outcome Measures
UCSD Performance-Based Skills Assessment, Brief 
(UPSA-B).24 The UPSA-B is a widely used measure of 
functional capacity that assesses financial and communi-
cation skills required for community living. Total scores 
could range from 0 to 100.
Social Skills Performance Assessment (SSPA).25 Social 
competence was assessed with the SSPA, a role-play mea-
sure in which participants were asked to initiate and main-
tain a conversation in 2 social situations: meeting a new 
neighbor and negotiating with a landlord to fix a leak. Role-
plays were audiotaped and coded by an expert rater blind to 
diagnosis on the following variables: interest, fluency, clar-
ity, focus, overall abilities, and social appropriateness. The 
landlord role-play was also coded for negotiation ability and 
persistence. The mean score across both role-plays was used 
as the dependent measure and could range from 1 to 5.
Specific Level of Functioning Scale (SLOF).26 Real-
world functional outcome was assessed via the 31-item 
version of the SLOF, an informant-rated measure of 
social functioning (interpersonal relationships and social 
acceptability) and community-living skills (participation 
in activities and work skills). Informants were identified 
by the participants and were high contact clinicians, fam-
ily members, or close friends. Ratings for each item were 
made on a 1–5 point scale with higher scores indicating 
better functioning. An average score across the entire 
measure was used as the dependent variable.
Procedures
All participants completed 2 study visits: baseline and a 
retest assessment completed 2–4 weeks after the initial 
visit (mean interval = 17.29 days). At visit 1, all partici-
pants provided informed consent and completed the 
social cognitive, neurocognitive, and functional outcome 
measures. The order of these task blocks was counterbal-
anced, and within the social cognitive battery, the order of 
individual tasks was counterbalanced as well. For patients, 
visit 1 also included diagnostic assessment and an evalua-
tion of symptom severity using the Positive and Negative 
Syndrome Scale.27 Diagnostic and symptom raters were 
trained to reliability using the established procedures at 
each site. At visit 2, symptom severity was reassessed in 
the patients, and all participants repeated the social cog-
nitive measures in the same order as their first visit. For 
TASIT, an alternative form (TASIT-B) was administered 
to all subjects at visit 2; however, alternative forms were 
not available for any other social cognitive task, so these 
were identical to visit 1.  Visit durations were approxi-
mately 3.5–4.5 hours for visit 1 and 3 hours for visit 2.
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Statistical Analyses
Score distributions of the social cognitive measures were 
first checked for normality by examining skew and kurtosis 
statistics and visually inspecting histograms. No measures 
required transformation; however, 1 control participant 
was an outlier on the Hinting task (< 3SD from the 
mean); these data were excluded from further analy-
ses. Test-retest reliability was computed using Pearson’s 
r correlation coefficients. Utility as a repeated measure 
was evaluated by assessing evidence for practice effects 
(paired-samples t-tests with Cohen’s dz) and floor/ceiling 
effects (number of participants scoring at/below chance 
levels or scoring 100%).
To examine relationship to functional outcome 
among patients, 3 steps were followed. First, correla-
tions were calculated between the visit 1 social cogni-
tive and neurocognitive measures and the 3 outcome 
measures. Second, those social cognitive tasks show-
ing a significant correlation with each outcome where 
then entered into regression models in a single block 
to assess the explanatory power of  the tasks as group. 
Third, hierarchical regression models were conducted 
with neurocognitive variables entered in block 1 and 
social cognitive variables entered in block 2. Together, 
these analyses allowed for an examination of  criterion 
validity and incremental validity beyond neurocognitive 
abilities.
Descriptive statistics assessed practicality and toler-
ability. Independent samples t-tests with Cohen’s d were 
used to examine group differences. Finally, internal con-
sistency was evaluated with Cronbach’s alpha.
Results
Participants
Across the 2 sites, 179 patients and 104 healthy con-
trols completed visit 1, with 171 and 98 participants, 
respectively, completing visit 2.  Groups did not differ 
on race, ethnicity, age, parental education, or estimated 
IQ. Patients completed fewer years of education than 
controls, and there were more males than females in 
the patient sample. Patients reported relatively low lev-
els of symptoms at visit 1, and there were slight reduc-
tions in positive and general symptoms at visit 2 (positive: 
t(170) = 2.05, P = .042, dz = .16; negative: t(170) = 2.54, 
P = .012, dz = .19). Demographic and clinical characteris-
tics are provided in table 1.
Site Effects
Site differences in patient performance on the social 
cognitive measures at visit 1 were examined. SMU 
patients scored higher than UM patients on both the 
Eyes task (t(178) = 4.65, P = .032, d = .33) and TASIT 
(t(178) = 3.95, P = .048, d = .31). No other comparisons 
were statistically significant.
Test-Retest Reliability
Adopting a range of Pearson’s r values of .6 to .8 as 
good,28,29 test-retest reliability was adequate for the 
majority of measures. Only the 2 bias measures of the 
AIHQ (ie, hostile and aggressive biases) showed inade-
quate values among patients. For healthy controls, test-
retest reliability was generally lower than in patients, with 
AIHQ-HB, Hinting task, TASIT and Trust task all hav-
ing values below benchmark standards (table 2).
Utility as a Repeated Measure
Among patients, all tasks except the Eyes task showed sta-
tistically significant differences between the first and sec-
ond administration (table 3). AIHQ-AB, BLERT, ER-40, 
Hinting, RAD and Trust all showed improved scores at 
visit 2, and TASIT, AIHQ-HB, and AIHQ-BS scores sig-
nificantly decreased between administrations. However, 
the effect sizes for these differences were all small (range 
0.15–0.27). Floor effects were most pronounced RAD, 
wherein 43% of patients scored at or below chance levels 
Table 1. Participant Demographic and Clinical Characteristics
Characteristic
Patients 
(n = 179)
Controls 
(n = 104)
N (%) N (%)
Male* 117 65 49 47
Race
 Caucasian 76 42 43 41
 African American 94 53 55 53
 Native American 1 1 0 0
 Asian 4 2 4 4
 Other 4 2 2 2
Ethnicity
 Hispanic 37 21 21 20
 Non-Hispanic 142 79 83 80
Diagnosis
 Schizophrenia 96 54
 Schizoaffective 83 46
Medication typea
 Typical 26 15
 Atypical 125 70
 Combination 3 2
Mean SD Mean SD
Age (years) 42.11 12.32 39.20 13.70
Education (years)* 12.70 2.14 13.43 1.66
Maternal education (years) 12.61 3.22 13.14 2.53
Paternal education (years) 13.04 3.75 13.43 2.49
WRAT-3 93.68 15.88 95.35 13.19
PANSS
 Positive total 16.14 5.79
 Negative total 13.72 5.29
 General total 30.83 7.99
Note: WRAT, Wide Range Achievement Test; PANSS, Positive 
and Negative Syndrome Scale.
aNineteen individuals were not taking antipsychotic medications, 
and medication information was missing for 6 individuals.
*P < .01.
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at visit 1. This percentage decreased to 33% at visit 2. For 
the remaining tasks, less than 7% of the sample scored at 
floor or ceiling.
Healthy control performance also showed prac-
tice effects for AIHQ, ER-40, and Hinting. TASIT 
performance again worsened at visit 2. Effect sizes for 
these differences ranged from small to medium. RAD 
continued to have a number of  participants, 12%, scor-
ing at floor levels. Additionally, approximately 7% of 
the sample scored at ceiling for the Hinting task at both 
time points.
Relationship to Functional Outcome
Correlations between the social and neurocognitive tasks 
and the functional outcome tasks for patients are pre-
sented in table 4. With the exception of the AIHQ and 
Trust tasks, social cognitive tasks showed significant 
positive correlations with outcomes. The magnitude of 
these relations ranged from small to medium (0.20–0.46). 
Neurocognitive tasks were also significantly related to 
outcomes with comparable magnitudes (0.17–0.54).
We assessed the explanatory power of social cognitive 
performance by first entering those tasks showing a sig-
nificant correlation with outcome as a single block. The 
social cognitive tasks significantly accounted for 31% of 
the variance in functional capacity as measured by the 
UPSA-B (adjusted R2 = .308, F(6,168) = 13.92, P < .001), 
16% of the variance in social competence as measured 
by the SSPA (adjusted R2 =  .156, F(6,167) = 6.35, P < 
.001), and 10% of the variance in real-world functioning 
indexed by the SLOF (adjusted R2 = .104, F(4,169) = 6.04, 
Table 2. Test-Retest Reliability and Internal Consistency
Task
Test-Retest 
Reliability  
(Person r)
Internal 
Consistency 
(Cronbach’s Alpha)
Patients 
(n = 171)
Controls 
(n = 98)
Patients 
(n = 179)
Controls 
(n = 104)
AIHQ
 Hostility bias (HB) .516 .572 .859 .846
 Aggression bias (AB) .572 .700 .422 .467
 Blame Score (BS) .738 .756 .491 .338
BLERT .699 .680 .737 .626
ER-40 .753 .753 .808 .645
Eyes .753 .761 .735 .673
Hinting .639 .424 .729 .563
RAD .751 .756 .717 .700
TASIT .600 .544 .807 .757
Trust .737 .597 .960 .900
Notes: AIHQ, Ambiguous Intentions Hostility Questionnaire; 
BLERT, Bell Lysaker Emotion Recognition Task; RAD, 
Relationships Across Domains; TASIT, The Awareness of Social 
Inferences Test.
Table 3. Utility as a Repeated Measure
Task
T1 T2
T2–T1 
Difference
Number at 
Floor/Ceiling
t P value Cohen’s dzMean SD Mean SD Mean SD T1 T2
Patients (n = 171)
 AIHQ-HB 2.38 0.61 2.21 0.64 −0.17 0.62 — — −3.57 <.001 0.27
 AIHQ-AB 1.88 0.39 1.95 0.44 0.06 0.39 — — 2.05 .04 0.16
 AIHQ-BS 8.76 2.85 8.42 3.06 −0.34 2.15 — — −2.06 .04 0.16
 BLERT 13.24 3.82 13.91 3.99 0.67 3.04 1/0 0/4 2.87 .005 0.22
 ER-40 29.69 5.37 30.42 4.95 0.73 3.65 1/0 0/0 2.62 .01 0.20
 Eyes 20.22 5.52 20.66 5.85 0.44 4.00 5/0 4/0 1.43 .15 0.11
 Hinting 13.65 3.80 14.25 3.68 0.60 3.18 0/2 0/2 2.46 .02 0.19
 RAD 24.79 5.79 25.86 5.70 1.07 4.06 77/0 56/0 3.40 .001 0.26
 TASIT 44.55 7.55 42.92 6.36 −1.63 6.31 12/0 9/0 −3.37 .001 0.26
 Trust −0.12 1.13 −0.002 0.91 0.12 0.77 — — 2.01 .05 0.15
Controls (n = 98)
 AIHQ-HB 2.00 0.60 1.78 0.53 −0.22 0.53 — — -4.19 <.001 0.42
 AIHQ-AB 1.83 0.26 1.82 0.31 −0.01 0.22 — — −0.28 .78 0.05
 AIHQ-BS 7.08 2.30 6.34 2.41 −0.73 1.65 — — −4.41 <.001 0.44
 BLERT 15.74 2.89 16.12 2.96 0.38 2.34 0/2 0/1 1.59 .11 0.16
 ER-40 32.61 3.53 33.13 3.41 0.52 2.44 0/0 0/0 2.11 .04 0.21
 Eyes 23.50 4.71 23.55 5.34 0.05 3.52 0/0 2/0 0.14 .89 0.01
 Hinting 16.85 2.01 17.45 1.50 0.59 1.93 0/6 0/7 3.02 .003 0.31
 RAD 29.87 5.21 30.45 5.61 0.58 3.80 12/0 9/0 1.52 .13 0.15
 TASIT 51.44 5.68 48.21 6.58 −3.22 5.91 0/0 0/0 −5.40 <.001 0.54
 Trust 0.18 0.60 0.24 0.58 0.06 0.53 — — 1.11 .27 0.11
Notes: AIHQ, Ambiguous Intentions Hostility Questionnaire; BLERT, Bell Lysaker Emotion Recognition Task; RAD, Relationships 
Across Domains; TASIT, The Awareness of Social Inferences Test.
499
SCOPE Psychometric Study
P < .001). When restricting the sample to individu-
als with high-quality informants (ie, professionals with 
mental health experience, n = 137),30 AIHQ-BS was also 
significantly correlated to SLOF scores, and the predic-
tive ability of the social cognitive variables improved 
to 16% variance in SLOF ratings (adjusted R2  =  .159, 
F(5,131) = 6.13, P<.001). Details are provided in table 5.
Next, we examined the incremental validity of the 
social cognitive tasks by determining whether they 
would significantly predict variance above and beyond 
neurocognitive performance (table 6). For UPSA-B, the 
neurocognitive variables alone predicted 31% of the vari-
ance in scores (adjusted R2 =  .310, F(5,165) = 16.29, P 
< .001), which significantly increased to 37% when the 
social cognitive variables were added (adjusted R2 = .372, 
F(11,159) = 10.16, P < .001; R2 change = .082, P = .002). 
Neurocognitive variables also significantly predicted 
social competence (SSPA) variance (adjusted R2 = .146, 
F(4,165)  =  8.23, P < .001). The inclusion of the social 
cognitive variables contributed an additional 7% to the 
total variance (R2 change  =  .068, P  =  .032), constitut-
ing a significant increase and bringing the overall model 
to approximately 19% of variance explained (adjusted 
R2 = .187, F(10,159) = 4.87, P < .001). For the SLOF, both 
models accounted for significant variance (neurocogni-
tive: adjusted R2 =  .085, F(4,166) = 4.93, P =  .001 and 
neurocognitive plus social cognitive: adjusted R2 = .112, 
F(8,162) = 3.67, P = .001), but the increase between mod-
els was not significant (R2 change = .047, P = .065). When 
including data only from high-quality informants, neuro-
cognitive performance alone accounted for 5% of the vari-
ance (adjusted R2 = .050, F(4,129) = 2.76, P = .03), and the 
combined social and neurocognitive variables accounted 
Table 5. Regression Models Demonstrating the Overall Contribution of the Social Cognitive Tasks to Outcomes
R2 Adjusted R2 F P b* t P sr2
UPSA total .332 .308 13.92 <.001
 BLERT −.08 −.88 .382 .003
 ER-40 .11 1.28 .20 .007
 Eyes .09 .99 .32 .004
 Hinting .29 3.91 <.001 .06
 RAD .19 2.29 .02 .02
 TASIT .13 1.47 .15 .008
SSPA average .186 .156 6.35 <.001
 BLERT .04 .39 .70 .000
 ER-40 .05 .48 .63 .001
 Eyes .08 .77 .44 .002
 BLERT .21 2.35 .02 .03
 Hinting .04 .52 .60 .001
 RAD −.02 −.26 .79 .000
 TASIT .19 1.94 .05 .02
SLOF-HQ .190 .159 6.13 <.001
 AIHQ-BS −.12 −1.52 .13 .01
 BLERT .38 3.83 <.001 .09
 Hinting −.01 −.08 .94 .000
 RAD −.05 −.47 .64 .001
 TASIT .08 .72 .47 .003
Notes: SLOF-HQ indicates ratings from high quality informants (ie, professionals with mental health experience). AIHQ, Ambiguous 
Intentions Hostility Questionnaire; BLERT, Bell Lysaker Emotion Recognition Task; RAD, Relationships Across Domains; TASIT, The 
Awareness of Social Inferences Test. b* indicates standardized coefficients. 
Table 4. Correlations between Social Cognitive Tasks and 
Functional Outcome Measures in Patients
UPSA Total SSPA Average SLOF Total
Social cognitive
 AIHQ-HB −.071 .063 −.058
 AIHQ-AB .041 .078 −.071
 AIHQ-BS −.005 .094 −.137
 BLERT .317*** .261*** .310***
 ER-40 .360*** .240*** .046
 Eyes .425*** .300*** .127
 Hinting .462*** .394*** .197**
 RAD .439*** .243** .202**
 TASIT .437*** .310** .304***
 Trust .052 −.030 .043
Neurocognitive
 Trails A −.270*** −.103 −.237**
 Symbol coding .264*** .301*** .263***
 HVLT-R .421*** .358*** .174*
 Letter number span .544*** .317*** .255**
 Animal naming .174* .168* .078
Notes: AIHQ, Ambiguous Intentions Hostility Questionnaire; 
BLERT, Bell Lysaker Emotion Recognition Task; RAD, 
Relationships Across Domains; SLOF, Specific Level of 
Functioning Scale; TASIT, The Awareness of Social Inferences 
Test.
*P < .05, **P < .01, ***P < .001.
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for 13% variance (adjusted R2  =  .133, F(9,124)  =  3.27, 
P  =  .001). The social cognitive tasks accounted for an 
additional 11% of variance above and beyond neurocog-
nition alone (R2 change = .113, P = .006).
Practicality and Tolerability
Ratings of practicality and tolerability were implemented 
approximately midway through the study duration, and 
thus 95 patients and 59 controls provided data. As seen in 
table 7, administration time was under 8 minutes for the 
majority of tasks. The RAD and TASIT each took more 
than twice as long as the other tasks. As expected, comple-
tion time for patients was longer than controls. Participants 
also rated all tasks to be pleasant with comparable ratings 
between tasks. The RAD and TASIT received the lowest 
ratings from both patients and controls.
Group Differences
Patient and control performance significantly differed on 
all measures and indices except for AIHQ-AB (table 8). As 
expected, on AIHQ-HB and AIHQ-BS, patients scored 
higher than controls, and on the remaining measures, 
Table 6. Final Regression Models Accounting for Additional Variance in Outcome beyond Neurocognitive Performance
UPSA-B SSPA SLOF SLOF-HQ
b* sr2 b* sr2 b* sr2 b* sr2
Block 1—Neurocognition
 Trails A −.157* .016* — — −.109 .008 −.060 .002
 Symbol coding −.106 .006 .136, .013 .069 .003 .007 .000
 HVLT-R .087 .004 .191* .021* −.028 .000 .005 .000
 Letter number span .310** .046** .071 .003 .087 .004 .072 .003
 Animal Naming −.050 .002 −.008 .000 — — — —
Block 2—Social cognition
 AIHQ-BS — — — — — — −.094 .008
 BLERT −.116 .007 .005 .000 .154 .015 .353** .076**
 ER-40 .094 .005 −.022 .000 — — — —
 Eyes .043 .000 .052 .001 — — — —
 Hinting .242** .041** .258** .047** .038 .001 −.020 .000
 RAD .082 .003 −.095 .004 −.060 .002 −.071 .003
 TASIT .090 .004 .059 .002 .158 .013 .065 .002
Overall model
 Adjusted R2 .372*** .187*** .112** .133**
 R2 change .082** .068* .047 .113**
Notes: SLOF-HQ indicates ratings from high quality informants (ie, professionals with mental health experience). AIHQ, Ambiguous 
Intentions Hostility Questionnaire; BLERT, Bell Lysaker Emotion Recognition Task; RAD, Relationships Across Domains; TASIT, The 
Awareness of Social Inferences Test. b* indicates standardized coefficients.
*P < .05, **P < .01, ***P < .001.
Table 7. Practicality and Tolerability
Task
Practicality  
(Administration Time in Minutes)
Tolerability  
(Participant Ratings)
Patients  
(n = 95)
Controls  
(n = 59)
Patients  
(n = 95)
Controls  
(n = 59)
Mean SD Mean SD Mean SD Mean SD
AIHQ 6.35 2.01 5.82 1.61 5.54 1.30 5.73 1.20
BLERT 7.09 1.50 6.94 0.99 5.14 1.72 5.54 1.58
ER-40 3.21 1.02 2.73 0.73 5.55 1.40 5.59 1.41
Eyes 6.56 3.56 5.45 2.58 5.43 1.59 5.31 1.33
Hinting 6.13 1.89 5.33 1.46 5.38 1.44 5.60 1.50
RAD 15.84 4.45 13.82 3.15 4.74 1.78 4.70 1.53
TASIT 17.92 3.93 17.46 2.12 5.04 1.59 4.83 1.67
Trust 4.46 2.78 3.48 1.29 5.28 1.66 5.19 1.76
Notes: AIHQ, Ambiguous Intentions Hostility Questionnaire; BLERT, Bell Lysaker Emotion Recognition Task; RAD, Relationships 
Across Domains; TASIT, The Awareness of Social Inferences Test.
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control participants outperformed patients. Effect sizes 
varied but were generally large (range: 0.65–1.05) with 
the exception of the trust task which showed only a small 
effect (d = 0.27).
Internal Consistency
Kraemer has pointed out that Cronbach’s alpha should 
not be used as a reliability coefficient and is therefore of 
limited utility in the evaluation of measures for use in clin-
ical trials.31 Cronbach’s alpha can however be informative 
during the development of a measure, and we have there-
fore chosen to include this information in the event that 
it may aid in the further development of these measures.
A Cronbach’s alpha of .80 is considered appropriate 
for research tools.32 For patients, almost all measures 
either approached or exceeded this value (table  2). The 
one notable exception was the AIHQ for which both 
the AB and BS indices were much lower, 0.42 and 0.49, 
respectively. These scales included the fewest number of 
items, which could explain the lower values.
Recommendations from Follow-up Panel
A subset of the original RAND Panel (participants listed 
in Appendix) and the study consultants reviewed the psy-
chometric data and classified each task as: Acceptable As 
Is, Acceptable with Modifications, or Not Recommended 
for Further Consideration. Consensus for these classi-
fications was achieved via a conference call. No panel-
ist reported financial conflicts of interest; however, Drs 
Green and Lysaker each reported involvement in the 
development of one of the measures under consideration. 
In addition, one of the Principal Investigators, who did 
not participate in the Rand Panel (DLP), also developed 
one of the measures under consideration (AIHQ).
BLERT, ER-40, and Hinting were all classified as 
Acceptable As Is. The panel did however express some 
concern about overlap between the BLERT and ER-40 
(r  =  .59 at both time points; supplementary table  1), 
commenting that the BLERT is currently more suit-
able because it predicted real-world functional outcome 
whereas the ER-40 did not. The Eyes task was also rated 
as acceptable, but a concern included the potential depen-
dence of performance on vocabulary and the somewhat 
limited relation with outcomes. The TASIT was also 
rated as acceptable, but the Panel noted a need to clarify 
whether the differences between performance at visits 1 
and 2 were due to interference from previous administra-
tion or non-equivalence between the 2 task forms.
AIHQ, RAD, and Trust were classified as Not 
Recommended for Further Consideration. For AIHQ, 
the primary concern was the limited relation with func-
tional outcomes. Concerns about the RAD included 
length, patient tolerability, and difficulty as a high pro-
portion of patients performed at chance levels. Lack of 
a unique contribution to outcomes was also considered. 
For Trust, concerns included a reduced ability to distin-
guish patients from controls and the lack of a relation 
with functional outcomes.
Discussion
In the third phase of the Social Cognition Psychometric 
Evaluation study, we conducted a systematic investiga-
tion of the reliability and validity of 8 social cognitive 
measures and presented our findings to a panel of experts 
to obtain consensus on which tasks could currently be 
recommended for use in clinical trials. Five social cogni-
tive tasks (BLERT, ER-40, Eyes, Hinting, and TASIT) 
displayed acceptable psychometric characteristics, while 
3 tasks (AIHQ, RAD, and Trust) showed weaker char-
acteristics, suggesting that they may be of more limited 
use in clinical trials. The BLERT and Hinting task were 
the strongest of the 5 acceptable tasks. Both showed 
adequate test-retest reliability, small practice effects, and 
limited potential for floor/ceiling effects. They also distin-
guished patient performance from controls, were well tol-
erated by patients, and could be administered relatively 
quickly. Notably these 2 tasks showed the strongest rela-
tion to functional outcomes and uniquely predicted vari-
ance in outcomes while controlling for all other social and 
neurocognitive variables. The Hinting task emerged as a 
uniquely significant predictor of functional capacity and 
social competence, and BLERT was the only uniquely 
significant predictor of real-world outcomes as rated by 
high-quality informants. The psychometric properties of 
these tasks therefore recommended them for use in clini-
cal trials seeking to improve those aspects of social cogni-
tion which have strong links to functioning; improvement 
on these tasks may be considered an intermediate target 
for treatments focusing on functional outcomes.
Table 8. Group Differences on Social Cognitive Measures
Task
Patients  
(n = 179)
Controls  
(n = 104)
t P Cohen’s dMean SD Mean SD
AIHQ-HB 2.38 0.60 1.99 0.60 5.29 <.001 .65
AIHQ-AB 1.89 0.38 1.83 0.26 1.46 .147 .18
AIHQ-BS 8.74 2.81 7.02 2.31 5.29 <.001 .67
BLERT 13.17 3.88 15.75 2.88 −6.38 <.001 .76
ER-40 29.55 5.40 32.80 3.54 −6.10 <.001 .71
Eyes 20.15 5.46 23.55 4.62 −5.58 <.001 .67
Hinting 13.59 3.87 16.82 2.05 −9.14 <.001 1.04
RAD 24.76 5.76 29.82 5.16 −7.37 <.001 .93
TASIT 44.43 7.64 51.48 5.62 −8.89 <.001 1.05
Trust −0.09 1.14 0.16 0.62 −2.33 .02 .27
Notes: AIHQ, Ambiguous Intentions Hostility Questionnaire; 
BLERT, Bell Lysaker Emotion Recognition Task; RAD, 
Relationships Across Domains; TASIT, The Awareness of Social 
Inferences Test.
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The ER-40, Eyes, and TASIT also generally showed 
adequate psychometric characteristics, but these tasks 
had some limitations. While each task was correlated 
with some outcomes and was included in the block of 
social cognitive variables that provided incremental valid-
ity for the prediction of outcomes beyond neurocogni-
tion, none emerged as uniquely significant. This raises 
questions of redundancy between tasks, particularly 
when tasks are drawn from the same social cognitive 
domain. For example, it is currently unclear whether the 
ER-40 offers a unique contribution beyond the BLERT. 
Additionally, previous work indicates that performance 
on Eyes requires a heavy demand on vocabulary,33 which 
may interfere with accurate measurement of social cogni-
tive ability. For TASIT, concerns exist about the equiva-
lence of test forms, and the longer administration time 
may be prohibitive for some clinical trials.
Three tasks, AIHQ, RAD, and Trust, showed less 
consistent properties that warrant caution for their 
use in clinical trials. The AIHQ bias scores (but not 
the blame score) showed low test-retest reliability, and 
the RAD showed considerable floor effects along with 
lower patient tolerability and one of  the longer admin-
istration times. The Trust task only weakly discrimi-
nated patient and control performance, and all 3 tasks 
showed limited correlations with outcomes. For these 
reasons, the reconvened expert panel recommended 
that these tasks be omitted from further study under 
the SCOPE project.
The ramifications of these omissions require consid-
eration. First, removal of the AIHQ and the Trust task 
eliminates the only bias measures in the battery. Attention 
has recently been drawn to the distinction between social 
cognitive capacities (eg, the ability to generate emotional 
state representations) and social cognitive biases (eg, the 
tendency to interpret any negative emotion as angry) with 
the idea that both are likely involved in social dysfunc-
tion and should be targets of remediation.34 The weaker 
psychometric properties of these tests do not negate the 
potential importance of studying biases. In fact, the func-
tional significance of attributional biases may be most 
salient on outcomes that assess aggressive behavior, rather 
than general social/instrumental function,35 and distrust 
biases are associated with important symptom dimen-
sions (eg, paranoia).36,37 Thus, while these tasks cannot 
currently be recommended for use in clinical trials (if  
general functional outcomes are the target), we encour-
age continued development in this area. Second, removal 
of the RAD currently leaves the domain of social per-
ception unrepresented. The omission of these tasks raises 
questions about how best to assess the full range of social 
cognitive processes in a clinical trial.
The future phases of SCOPE will attempt to address 
this question as well as those limitations identified by the 
panel for the Eyes task and TASIT. The goals of phase 
4 will be 2-fold. First, given that experts in our previous 
survey considered the domains of attribtuional style 
and social perception to be important for the study of 
social cognition in schizophrenia,6 we will make one more 
attempt to find suitable assessments for these domains. 
We will re-examine the data gathered from our previous 
expert survey and consult directly with experts in the field 
to identify other measures that may be suitable replace-
ments. Second, phase 4 will also collect new pilot data on 
a modified protocol. For Eyes, we have created a version 
of the task that provides definitions on the same screen 
as the stimuli, which may reduce dependence on vocabu-
lary. We will also administer TASIT forms in a counter-
balanced order to determine the equivalence of forms. 
Additionally, we will collect response time (RT) data on 
BLERT, ER-40, Eyes, and TASIT. These tasks are well 
suited for the collection of RT data, and this information 
may aid in the prediction of functional outcomes. The 
final phase of SCOPE, Phase 5, will recruit another large 
sample of patients and controls to investigate the psycho-
metric properties of the new attributional style and social 
perception measures. Modifications to the remaining 
tasks that appear successful based on the pilot data from 
phase 4 will also be validated with this larger sample.
Finally, potential limitations of this study should be 
considered. The tasks evaluated here were identified 
based upon expert surveys and a consensus process, and 
it is currently unclear if  these tasks are truly the best mea-
sures of social cognition. Future efforts may benefit from 
utilizing brain-based or social psychological frameworks 
to identify tasks for evaluation. Additionally, within the 
patient group, all tasks except the Eyes task showed small 
but significant practice effects. It is possible that our 
short test-retest interval contributed to these improve-
ments; however, the presence of these effects highlights 
the need for equivalent alternative forms of these mea-
sures. Likewise, although the BLERT and Hinting task 
were judged by the panel to be ready for use, the test-
retest reliabilities of these tasks fell at the lower end of 
the “good” range. Users of these tasks should therefore 
interpret their data with these lower values in mind. 
Thought should also be given to how the present results 
compare to previous reports using these measures. The 
SCOPE patient sample may differ in key ways from other 
samples, eg, in terms of educational or IQ levels, and this 
might have impacted some of the psychometric scores. 
However, the large, diverse sample used here is represen-
tative of individuals targeted for clinical trials.38 Thus, 
current psychometric data indicate that the BLERT and 
Hinting task are appropriate for use in clinical trials 
seeking to improve social cognition in individuals with 
schizophrenia. 
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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